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For isolated care facilities and large-scale epidemiology projects,
it may be necessary to consider mailing blood samples to a central
laboratory. However, in order to yield reliable measurements,
analytes must be stable for several days. Blood phosphate concentra-
tion is routinely measured in renal patients and is also of research in-
terest as an emerging risk factor for cardiovascular disease [1,2].
However, as a result of increased hydrolysis of intracellular
phosphate esters with subsequent efﬂux from the red cells, serum
phosphate concentration increases by about 20% in blood left unpro-
cessed in plain glass tubes at room temperature for 24 h [3]. Separa-
tor tubes contain a polymer gel that reversibly liqueﬁes during
centrifugation, forming a barrier between serum/plasma and cells.
Whilst phosphate concentration has been reported to increasemark-
edly in uncentrifuged gel tubes stored at room temperature for 1 day
[4–6], stability in centrifuged tubes, particularly over longer periods
and at the high concentrations seen in renal patients, is less certain
[3,5,7]. Using delays in sample processing that might typically be
expected, we have investigated whether gel barrier separator tubes,
centrifuged prior to posting, enable reliable measurement of phosphate
concentration.
A pilot study was performed to establish the feasibility of mailing
centrifuged blood samples from a kidney unit to a central laboratory.
Ethical approval was obtained to collect 25 mL of blood from
haemodialysis (HD) patients and 50 mL of blood from healthy volun-
teers in a single phlebotomy (Oxfordshire REC-A, reference numbers:
06/Q1604/108 & 11/SC/0498). The blood was collected from clinical
areas and sent to the local hospital laboratory using routine portering.
Samples were centrifuged (but not aliquoted) and the collection tubes
were then posted by standard mail to a central laboratory. About 90%
of samples were centrifuged within 4 h of collection and all samples
were received at the central laboratorywithin 2working days of posting.
After establishing feasibility, a more formal stability study was per-
formed. Blood samples were collected into serum separator tubes
(SST; Becton Dickinson) and, immediately after clotting, one tube
from each individual was centrifuged (1300 g at 18 °C for 10 min) and
the supernatant immediately aliquoted and frozen at −80 °C (refer-
ence tube). The remaining SSTs from each participant were kept at am-
bient temperature (18–24 °C) and processed in one of the following
ways before freezing the serum at−80 °C:
1. A delay of 4, 8 or 20 h before centrifugation and immediate aliquoting
2. Immediate centrifugation followed by a 2 or 4 days' delay before
aliquoting
3. A 4 hour delay in centrifugation followed by 0, 2 and 4 days' delay
before aliquoting.http://dx.doi.org/10.1016/j.cca.2014.09.025
0009-8981/© 2014 Elsevier B.V. All rights reserved.To mimic the postal system, samples were periodically agitated by
inversion. Sample aliquots for each individual from all conditions and
time-points were thawed and analysed together in a single run on a
Beckman Coulter AU680 analyser (within-run coefﬁcient of variation
b1% at 1.7 mmol/L). Statisticalmethods are summarized in Supplemen-
tary appendix.
1. The effect of a delay in centrifugation
Mean (standard deviation [SD]) serum phosphate concentration in
reference samples from 33 healthy volunteers was 1.11 (0.18) mmol/L
and 1.73 (SD 0.47) mmol/L in 20 HD patients. Blood phosphate
instability in unprocessed separator-gel tubeswas conﬁrmed in healthy
volunteers: compared to reference tubes,mean phosphate concentration
in tubes stored at room temperature for 4 days before centrifugation and
immediate aliquoting increased by 113% (95% CI 100, 127%).
A delay in centrifugation of 4 h caused serum phosphate concentra-
tion to decrease on average by 1.5% (-2.2, -0.7%) in healthy volunteers
and by 0.2% (−1.1, 0.7%) in HD patients. A delay of 8 h led to an average
decrease in serum phosphate concentration of 3.3% (-4.6, -2.1%) in
healthy volunteers and 2.8% (-5.4, -0.1%) in HD patients (Table 1). The
increasinglywide conﬁdence intervalswith increasing delay in centrifu-
gation indicate the start of sample degradation. Although, by 4 h, no
samples in either group had changed by more than 0.1 mmol/L, by
8 h, 3% of samples from healthy volunteers and 20% from HD patients
had, and by 20 h, 27% of healthy volunteers and 40% of HD patient sam-
pleswere also no longer considered suitable for clinical use (Table 1 and
Supplementary Fig. 1A).
2. The effect of a delay in aliquoting
Compared to the reference tube, serum phosphate concentration in
immediately centrifuged SSTs aliquoted after a 4 day delay increased
on average by 5.3% (3.7, 6.9%) in healthy volunteers and 3.6% (2.5,
4.7%) in HD patients (p for difference between groups = 0.08; Table 1
and Supplementary Fig. 1B). About 10% of samples from both healthy
volunteers and HD patients respectively were no longer considered
suitable for clinical use.
3. The combined effect of a delay in centrifugation and delay
in aliquoting
Due to ethical limitations, sufﬁcient sample to complete this experi-
ment was only available in healthy volunteers. The combined effect of a
4 hour delay in centrifugation, followed by an increasing delay in
aliquoting from 0 to 4 days caused serum phosphate concentration in
healthy volunteers to change from an average decrease of 1.5% (-2.2,
-0.7%) at day 0 to an average increase of 2.9% (1.7, 4.2%) at day 4 (p
for trend over time b0.0001; Table 1 and Supplementary Fig. 1C).
Under these conditions all of the samples received within 2 days, and
97% of samples received within 4 days were suitable for clinical use.
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113Letter to the EditorThese data show that phosphate concentration in the blood left
unprocessed in gel-based separator tubes more than doubles over a
4 day period, but this change is reduced to 5% if the sample is centri-
fuged before this delay. This change was greater than could be ex-
plained by analytical imprecision alone (the acceptable limits of
change was ±0.3% [8]). Nevertheless, it represented very signiﬁcant
stabilisation compared to unprocessed samples.
The proportion of samples that changed bymore than 0.1 mmol/L of
the true value was used to quantify the proportion of samples that had
degraded to the point atwhich theywould no longer be considered clin-
ically useful. By such criteria, 97% of samples from healthy volunteers
were clinically useful when centrifuged within 4 h of collection and
aliquoted at 4 days. If samples from HD patients were subject to the
same experiment, perhaps at least 90% would remain clinically useful.
A longer delay between centrifugation and aliquoting (up to 8 h)
might also be permissible, particularly if samples were received within
2 days (as was observed in our initial pilot study). These results suggest
that gel-separator tubes, centrifuged prior to posting, stabilise serum
phosphate sufﬁciently long to allow for reliable results from mailed
blood samples, and suchmethodology could be tested on other analytes
previously thought too unstable for measurement in mailed samples.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.cca.2014.09.025.
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